AFP、AFU、CA19-9在原发性肝癌诊断中的应用价值

The Application Value ofAFP, AFU, CA19,9 in Diagnosing HCC

目的：探讨甲胎蛋白（AFP）、糖类抗原19-9（CA19-9）、a-L岩藻糖苷酶（AFu）联合检测在原发性肝癌诊断中的应用价值。方法：将50例原发性肝癌患者的资料记为观察组，50例肝炎、肝硬化患者的资料作为对照组，所有患者均进行AFP、AFU、CA19—9浓度及阳性检测，以评价AFP、AFU、CAl9．9联合检测在原发性肝癌患者诊断中的应用价值。结果：观察组患者AFP、AFU、CA19．9浓度均高于对照组（P〈0．05）；三项指标联合检测原发性肝癌的敏感性明显高于单项检测（P〈0．05）。结论：AFP、AFU、CA19—9联合检测能提高原发性肝癌诊断阳性率，有利于原发性肝癌患者的早期诊断与治疗。

Objective： To investigate the application value of alpha-fetoprotein （AFP）, carbohydrate antigen 19-9 （CA19-9） and a-L fucosidase （AFU） joint detection in diagnosing HCC. Methods： 50 cases of HCC patients＇ data were incorporated into observation group, and 50 cases of hepatitis and cirrhosis patients＇ data were incorporated into control group, all patients had been tested the concentration and detection rate of AFP, AFU and CAt9-9 to evaluate the application value ofAFP, AFU and CA19-9 joint detection in diagnosing HCC. Results： The concentration ofAFP, AFU and CA 19-9 in observation group was higher than those in control group （P〈0.05）; the sensitivity of the three indicators joint detection for HCC was sig- nificantly higher than that by individual test （P〈0.05）. Conclusion： AFP, AFU and CA19-9 joint detection can improve the diagnostic yield of HCC, which is beneficial to get early diagnosis and treatment for HCC patients.